Creating new treatments targeting a specific enzyme in breast cancer
Development of a new class of BLVRB-targeted redox therapeutics in breast cancer
This study is looking at new ways to help treat breast cancer by targeting a specific enzyme that helps cancer cells survive stress, with the hope of making these cells easier to kill or more responsive to treatments like chemotherapy and radiation.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Blood Cell Technologies, LLC NIH-funded |
| Lab location | 1 site (Stony Brook, UNITED STATES) |
| Project ID | NIH-10759653 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies that target the enzyme BLVRB, which plays a crucial role in helping breast cancer cells survive oxidative stress. By understanding how cancer cells adapt their antioxidant defenses, the research aims to create treatments that can either kill these cancer cells or make them more sensitive to existing therapies like chemotherapy and radiation. The approach involves studying the unique metabolic processes of cancer cells compared to normal cells, providing a potential new avenue for effective breast cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who may benefit from new therapeutic options targeting oxidative stress mechanisms.
Not a fit: Patients with non-breast cancer malignancies or those whose cancer is not influenced by oxidative stress mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting antioxidant pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Stony Brook, UNITED STATES
- Blood Cell Technologies, LLC — Stony Brook, United States (Active)
Researchers
- Principal investigator: Marchenko, Natalia — Blood Cell Technologies, LLC
- Study coordinator: Marchenko, Natalia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.